Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

ART, PBS, pure bioresorbable scaffold, CE Mark
Feature

May 26, 2015 — Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next ...

Home May 26, 2015
Home
News

May 22, 2015 — Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus ...

Home May 22, 2015
Home
News

May 18, 2015 — Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its ...

Home May 21, 2015
Home
News

May 19, 2015 — Abbott announced that it has received CE Mark for the latest advancement of its Absorb stent system ...

Home May 19, 2015
Home
News

May 11, 2015 — Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth ...

Home May 11, 2015
Home
News

February 19, 2015 — Biotronik announced the completion of enrollment in the BIOSOLVE-II trial — a clinical study investi ...

Home February 19, 2015
Home
News

February 17, 2015 — Micell Technologies, Inc. announced the commercial availability of the MiStent sirolimus-eluting abs ...

Home February 17, 2015
Home
News

February 12, 2015 — A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The ...

Home February 12, 2015
Home
bioresorbable stents
Feature | Dave Fornell
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely ...
Home December 31, 2014
Home
News

December 31, 2014 — Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The ...

Home December 31, 2014
Home
News

December 10, 2014 — In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific ...

Home December 10, 2014
Home
News

Nov. 14, 2014 — Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable ...

Home November 14, 2014
Home
News

By Dave Fornell, editor of DAIC Magazine

The key take away messages from the 26th annual Transcatheter Cardiovascular ...

Home November 03, 2014
Home
Feature

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioreso ...

Home October 08, 2014
Home
News

October 7,2014 — Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II ...

Home October 07, 2014
Home
Subscribe Now